Skip to main content

Medical Services

Kloxxado, a new nasal spray product that delivers 8 mg of naloxone to treat opioid overdose—double the 4 mg found in Narcan—has received FDA approval.
Officials from Massachusetts discuss the development of best practices for documentation and measurement to support post-overdose outreach programs, an increasingly popular concept across the U.S.
As part of its Project DAWN initiative, MetroHealth in Cleveland has outfitted an RV it can use to distribute naloxone, serve as a syringe exchange and provide other resources to at-risk individuals in Northeast Ohio.
Johns Hopkins Medicine announced that it is collaborating with 14 other Maryland hospitals on a five-year initiative aimed at reducing the use of emergency departments and police for substance use and mental health crises.
A long-term safety study of extended-release buprenorphine illustrates a safety profile comparable to that of the sublingual version of the drug.
Click here and listen to Dr. Patricia Essilfie, a physician at St. John’s Well Child, as she describes how the once limited resources and treatment plans for smokers at St. John’s, were transformed…
Back to Top